| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Centessa Pharmaceuticals plc American Depositary Shares (NASDAQ: CNTA)
CNTA Technical Analysis
4
| As on 15th May 2025 CNTA STOCK Price closed @ 12.59 and we RECOMMEND Buy for LONG-TERM with Stoploss of 10.52 & Strong Buy for SHORT-TERM with Stoploss of 7.49 we also expect STOCK to react on Following IMPORTANT LEVELS. |
CNTASTOCK Price
| Open | 12.21 | Change | Price | % |
| High | 12.68 | 1 Day | 0.32 | 2.61 |
| Low | 11.94 | 1 Week | 0.58 | 4.83 |
| Close | 12.59 | 1 Month | -1.11 | -8.10 |
| Volume | 509183 | 1 Year | 6.09 | 93.69 |
| 52 Week High 19.03 | 52 Week Low 5.92 | ||||
NASDAQ USA Most Active Stocks
| NCNA | 0.05 | 66.67% |
| AMRS | 0.14 | 100.00% |
| GNLN | 0.01 | 0.00% |
| PLUG | 0.70 | -11.39% |
| NVDA | 134.83 | -0.38% |
| TAOP | 0.28 | 40.00% |
| HCTI | 0.04 | -81.82% |
| LMDX | 0.02 | 0.00% |
| AKTS | 0.04 | 0.00% |
| EKSO | 0.40 | -11.11% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| CNTA Daily Charts |
CNTA Intraday Charts |
Whats New @ Bazaartrend |
CNTA Free Analysis |
|
|
CNTA Important Levels Intraday
| RESISTANCE | 14.02 |
| RESISTANCE | 13.56 |
| RESISTANCE | 13.28 |
| RESISTANCE | 12.99 |
| SUPPORT | 12.19 |
| SUPPORT | 11.90 |
| SUPPORT | 11.62 |
| SUPPORT | 11.16 |
CNTA Forecast May 2025
| 4th UP Forecast | 16.93 |
| 3rd UP Forecast | 15.54 |
| 2nd UP Forecast | 14.68 |
| 1st UP Forecast | 13.82 |
| 1st DOWN Forecast | 11.36 |
| 2nd DOWN Forecast | 10.5 |
| 3rd DOWN Forecast | 9.64 |
| 4th DOWN Forecast | 8.25 |
CNTA Weekly Forecast
| 4th UP Forecast | 16.27 |
| 3rd UP Forecast | 15.09 |
| 2nd UP Forecast | 14.36 |
| 1st UP Forecast | 13.63 |
| 1st DOWN Forecast | 11.55 |
| 2nd DOWN Forecast | 10.82 |
| 3rd DOWN Forecast | 10.09 |
| 4th DOWN Forecast | 8.91 |
CNTA Forecast2025
| 4th UP Forecast | 38.62 |
| 3rd UP Forecast | 30.27 |
| 2nd UP Forecast | 25.11 |
| 1st UP Forecast | 19.95 |
| 1st DOWN Forecast | 5.23 |
| 2nd DOWN Forecast | 0.07 |
| 3rd DOWN Forecast | -5.09 |
| 4th DOWN Forecast | -13.44 |
Centessa Pharmaceuticals plc American Depositary Shares ( NASDAQ USA Symbol : CNTA )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
CNTA Business Profile
Centessa Pharmaceuticals Limited, a pharmaceutical company, develops and delivers life-altering and life-enhancing medicines to patients. Its products pipeline include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase 3 clinical development for the treatment of autosomal dominant polycystic kidney disease; SerpinPC, an activated protein C inhibitor, which is in Phase 2a clinical development for the treatment of hemophilia A and B; Imgatuzumab, an anti-EGFR monoclonal antibody expected to enter a Phase 2 clinical trial for the treatment of cutaneous squamous cell carcinoma, as well as is being considered for the treatment of other solid tumors in the context of combination treatment with immunotherapy; and ZF874, a small molecule chemical chaperone folding corrector of the Z variant of alpha-1-antitrypsin in Phase 1 clinical development for the treatment of alpha-1-antitrypsin deficiency. The company's preclinical product candidates comprise ZF887 for alpha-1-antitrypsin deficiency; MGX292 for pulmonary arterial hypertension; CBS001 for idiopathic pulmonary fibrosis; CBS004 for systemic sclerosis and lupus; LB1 and LB2 for solid tumors; Oral OX2R Agonist and Intranasal OX2R Agonist for narcolepsy type 1; Dual STAT3/5 Degrader for hematological malignancies; EGFR Ex20 and EGFR-C797S inhibitors for non-small cell lung cancer; and next generation EGFR inhibitors. The company was formerly known as United Medicines Biopharma Limited and changed its name to Centessa Pharmaceuticals Limited in February 2021. Centessa Pharmaceuticals Limited was incorporated in 2020 and is based in Cambridge, the United Kingdom. Address: The Dorothy Hodgkin Building Babraham, Cambridge, United Kingdom, CB22 3FH
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service